{"product_id":"recombinant-conus-kinoshitai-mu-conotoxin-kiiib-partial-bhp10513687","title":"Recombinant Conus kinoshitai Mu-conotoxin KIIIB, partial","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eRecombinant Conus kinoshitai Mu-conotoxin KIIIB, partial is a recombinant protein preparation from Conus kinoshitai (Kinoshita's cone) designed for use in assay development, binding studies, and functional characterization. Key attributes such as expression system, expressed region, and affinity tag(s) help researchers match the reagent to specific experimental readouts.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e Yeast expression is commonly used for rapid, scalable production. For targets that require glycosylation or other post-translational modifications, consider how a prokaryotic system may affect folding or activity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression region:\u003c\/strong\u003e The expressed fragment (5-20aa) focuses the reagent on a defined domain\/segment, which can influence binding interfaces and epitope availability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTag(s)\/format:\u003c\/strong\u003e His\/SUMO tags can support purification and detection in pull-down or binding assays; confirm that the tag position does not interfere with the interaction of interest.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e ≥90% (SDS-PAGE) provides a quick checkpoint for reagent quality in downstream analytical workflows.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Supplied as Liquid or Lyophilized powder; select the format that best fits your lab’s handling and aliquoting preferences.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eRecombinant design choices (expression host, fragment boundaries, and tag configuration) help balance yield, solubility, and assay compatibility. Choose conditions and controls that match the recombinant format to your experimental question.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eCkin-MuConotoxinK\u003c\/strong\u003e has been reported to be involved in Mu-conotoxin KIIIA-P1: mu-conotoxins block voltage-gated sodium channels (Nav). This toxin potently blocks Nav1.2\/SCN2A (IC(50)5-124 nM), Nav1.4\/SCN4A (IC(50)=20-90 nM), and Nav1.7\/SCN9A (IC(50)=290-413 nM). It moderately blocks Nav1.1\/SCN1A, and mNav1.6\/SCN8A. It also shows a very low activity on Nav1.3\/SCN3A. This toxin binds a microsite within the pore different from the tetrodotoxin binding site 1 (tested on Nav1.2). The block is partial, with a residual current that can be completely blocked by TTX. The toxin probably docks at a more superficial site in the outer vestibule of the channel than does TTX. On rNav1.2\/SCN2A, it produces a block that is only partially reversible. The block of Nav1.7 is modified when beta-subunits are coexpressed with the alpha subunit. Hence, blocks of channels containing beta-1 and beta-3 subunits are more potent (compared to channels without beta subunits), whereas blocks of channels containing beta-2 and beta-4 subunits are less potent (compared to channels without beta subunits). ; Mu-conotoxin KIIIA-P2: This toxin potently blocks Nav1.2\/SCN2A (Kd=230 nM, IC(50)=1.37 uM) and Nav1.4\/SCN4A (Kd=830 nM, IC(50)=2 uM). It also moderately blocks Nav1.7\/SCN9A (Kd=1.57 uM, IC(50)=5.4 uM). In addition, this toxin may also inhibit other sodium channels, as does Mu-conotoxin KIIIA-P1. ; Mu-conotoxin KIIIA-N: This toxin moderately blocks Nav1.2\/SCN2A (IC(50)=875 nM), Nav1.4\/SCN4A (IC(50)=472 nM), and Nav1.7\/SCN9A (IC(50)=887 nM). ; Mu-conotoxin KIIIB-P1: This toxin potently blocks Nav1.2\/SCN2A (Kd=470 nM). In addition, this toxin may also inhibit other sodium channels, as does Mu-conotoxin KIIIA-P1. ; Mu-conotoxin KIIIB-P2: This toxin potently blocks Nav1.2\/SCN2A (Kd=26 nM). In addition, this toxin may also inhibit other sodium channels, as does Mu-conotoxin KIIIA-P1.. When interpreting results, consider species context, domain architecture, and whether the recombinant format represents full-length or a defined region.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eIncreasing use of recombinant proteins as standardized reagents for cross-study comparability in quantitative assays.\u003c\/li\u003e\n\u003cli\u003eStructure-guided design of domain fragments to dissect binding interfaces and functional regions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBinding and interaction assays:\u003c\/strong\u003e quantify partner binding and rank conditions using plate-based formats or biophysical methods (SPR\/BLI).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCell-based functional studies:\u003c\/strong\u003e evaluate dose–response and time-course effects in relevant cell systems when the target acts extracellularly or through receptor engagement.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay development:\u003c\/strong\u003e use as a standard, spike-in control, or positive control where consistent specifications are required.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically relies on relative comparisons (treated vs control, mutant vs wild-type, or dose\/time series) using consistent sample handling and appropriate normalization.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-translational modifications:\u003c\/strong\u003e expression system can affect glycosylation and processing; interpret differences cautiously when comparing to native protein.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsoforms and domains:\u003c\/strong\u003e expressed regions may not capture all isoform-specific features; match fragment boundaries to your assay’s binding site.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControls:\u003c\/strong\u003e include blank matrix controls, tag-only controls (where relevant), and orthogonal readouts (e.g., WB\/qPCR\/ELISA) to support interpretation.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProt Knowledgebase entry for Ckin-MuConotoxinK — UniProt — https:\/\/www.uniprot.org\/ - NCBI Gene for Ckin-MuConotoxinK — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - RCSB Protein Data Bank — RCSB PDB — https:\/\/www.rcsb.org\/ - PubMed (reviews and primary literature) — NCBI — https:\/\/pubmed.ncbi.nlm.nih.gov\/ - Ensembl gene summary — Ensembl — https:\/\/www.ensembl.org\/ --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53059058205037,"sku":"CSB-YP313491COP-1MG","price":2959.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53059213295981,"sku":"CSB-YP313491COP-100UG","price":826.0,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53059213328749,"sku":"CSB-YP313491COP-20UG","price":436.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-YP313491COP-SDS.jpg?v=1772271465","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-conus-kinoshitai-mu-conotoxin-kiiib-partial-bhp10513687","provider":"BioHippo","version":"1.0","type":"link"}